Format

Send to

Choose Destination
Nat Med. 2014 Oct;20(10):1126-9. doi: 10.1038/nm.3702. Epub 2014 Sep 7.

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Author information

1
Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
2
1] United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA. [2] Integrated Research Facility, NIAID, NIH, Fort Detrick, Maryland, USA (A.N.H., J.C.J. and L.H.), and Sanofi, Cambridge, Massachusetts, USA (G.J.N.).
3
1] Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA. [2].
4
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
5
Okairos, Rome, Italy.
6
1] Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA. [2] Integrated Research Facility, NIAID, NIH, Fort Detrick, Maryland, USA (A.N.H., J.C.J. and L.H.), and Sanofi, Cambridge, Massachusetts, USA (G.J.N.).
7
1] Okairos, Rome, Italy. [2] Centro Ingegneria Genetica (CEINGE), Naples, Italy. [3] Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
8
Keires AG, Basel, Switzerland.

Abstract

Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV challenge.

PMID:
25194571
DOI:
10.1038/nm.3702
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center